An observational study in Sepsis, Septic Shock and Immunoparalysis in Septic Shock, sponsored by Artcline GmbH. Recruiting at 2 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Artcline GmbH · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Shock, Septic with a site in Germany — 7 open to participants now, 7 under way, none of them phase 3. Shock, Septic · Germany.
Among the 56 studies in Shock, Septic with a site in Germany, this one is the 15th largest by planned enrollment of the 26 observational ones that give a count, is one of 2 that started in 2025, is one of 27 observational ones, and was the 55th registered.
1,079 studies on the registry are indexed under Shock, Septic; 233 are open to participants now.
Browse Shock, Septic studies →7 of the 56 studies in Shock, Septic with a site in Germany are open now. Recruiting first, the newest first:
Hannover Medical School · Sites in Germany, Austria, Switzerland
Ages 18–80
Charite University, Berlin, Germany · Sites in Germany
Ages 18+
CytoSorbents, Inc · Sites in Germany, Austria, Italy and 3 more countries
Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps · Sites in Germany
Ages 18–99
RWTH Aachen University · Sites in Germany, Austria
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 137 Shock, Septic studies recruiting now, 102 (74%) set no upper age limit and 19 (14%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 8
First in 2002; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 110 across 407 observational studies indexed under Shock, Septic.
Median enrollment 277 across the 29 interventional studies, 275 across the 26 observational. Of the 33 that completed or were terminated, 4 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 56 have an industry lead sponsor. The 10 most frequent:
Artcline GmbH is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Artcline GmbH has 1 study filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
4 of the studies in Shock, Septic with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05688774Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe SepsStudy of Progression of Community Acquired Pneumonia in the Hospital in Patients With More Severe Preexisting Diseases and Immunosuppression | 2027-02-28 |
| NCT07388628Artcline GmbHARTICE® Real Data Collection & Observational Trial, Phase 4 Study | 2027-09 |
| NCT03334006RWTH Aachen UniversityProspective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis | 2027-09 |
| NCT07817043University Medicine GreifswaldMicrobiology Operations & Time Optimization in Sepsis | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 56 studies in Shock, Septic with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objectives of this registry study are to:
1,079 studies on the registry are indexed under Shock, Septic; 233 are open to participants now.
This study's planned enrollment of 200 is above the median of 110 across 407 observational studies indexed under Shock, Septic.
Browse Shock, Septic studies →Artcline GmbH is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Subjects ≥ 18 years who are planned to receive ARTICE® treatment during their ICU stay
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
Change in SOFA score D0 to SOFA Score D7 (or after last ARTICE® treatment, if later as D7).
SOFA Score is the Sequential Organ Failure Score providing information about mortality risk, 6 organs or organ systems are assesed using specific parameters, both the sum of the points and the point development of the individual organs can be considered, normal function of organ/organ system has 0 points, severely impacted function do have 4 point, in total you can have 0 points (every organ/organ system is normale) as a minimum and 24 points as maximum (severely impacted organ/organ system)
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Changes in general SOFA score and SOFA sub scores.
SOFA Score is the Sequential Organ Failure Score providing information about mortality risk, 6 organs or organ systems are assesed using specific parameters, both the sum of the points and the point development of the individual organs can be considered, normal function of organ/organ system has 0 points, severely impacted function do have 4 point, in total you can have 0 points (every organ/organ system is normale) as a minimum and 24 points as maximum (severely impacted organ/organ system)
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Changes in standard lab and inflammatory biomarkers.
standard lab and inflammatory biomarkers for exampample are: ferritine, total bilirubin, kreatinine, CRP, lactate, gammaglobuline, amount of the different blodd cell types, like neutrophils, lymphocytes
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Hospital survival rates.
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Apache II Score.
APACHE II is a clinical rating system for evaluating the severity of an illness and the risk of death in intensive care medicine; score includes information on the patient's current condition, age and concomitant diseases, values are collected over 24 hours, highest value is included in calcutaion; the score can be at minimum 0 points (lightly risk of death) and at maximum 71 (very high risk of death)
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Length of ICU stay (days).
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Mechanical ventilation days.
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Renal replacement therapy days.
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Vasopressor therapy days.
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Frequency of secondary infections.
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Type of secondary infections: it will be divided into viral, bacterial or fungi infection.
It is recorded whether the infection is viral, bacterial, or caused by fungi. And in case of bacterial infection it will be recorded weather, it is gram-positive or gram-negative bacterial infection.
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Changes in the physiological parameter heartrate.
as physiological parameter will be measured heartrate in bpm
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Changes in physiological parameter blood pressure.
as physiological parameter will be measured systolic and diastolic blood pressure in mmHg.
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Changes in physiological parameter body temperature.
as physiological parameter will be measured body temperature in °C
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Changes in physiological parameter mean arterial pressure.
as physiological parameter will be measured mean arterial pressure in mmHG
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Complications related to the ARTICE® therapy application.
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.
Of 202 observational studies under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 24 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Artcline GmbH